
🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets128K
- Following139
- Followers42.9K
- Likes14K
Pinned Tweet
🎸 #UromigosLIVE 2026: the conversation on X 📊
THE FINAL NUMBERS Coverage by @OncoAlert 🚨
Nashville | Nov 13–14 🌍
5.7M potential reach
💬 3,200 posts & mentions
🔥 4,200 engagements
🇺🇸 USA 59.5% 🇮🇹 Italy 13.3% 🇪🇸 Spain 10% 🇮🇳 India 4.6% 🇯🇵 Japan 🇩🇪 Germany 🇸🇦 Saudi Arabia 🇦🇪 UAE 🇳🇱 Netherlands
🏆 Thank you to every #UroVoice who amplified the meeting, and to Tom & Brian for an unforgettable #UromigosLIVE 🙏 WE ARE ALL OncoAlert 🌐
Source: Talkwalker, X, Nov 10–16 @Uromigos @tompowles1 @brian_rini @shilpaonc @nataliagandur @PGrivasMDPhD @weoncologists @neerajaiims @Dr_Aggen @NazliDizman @montypal @AmandaNizamMD @scserendipity1 @DrKarineTawagi @CParkMD @TiansterZhang @OncoReporte @dralsharm @crisbergerot @UroDocAsh @RenoHemonc
OncoAlert retweeted
🎥 T-cell engagers in renal cell carcinoma: is the sun finally coming out?
At #UromigosLive 2026 in Nashville, @tompowles1 and @brian_rini discuss the CD3 x ENPP3 bispecific data @montypal presented at #ESMO26 :
🔹 ENPP3 is expressed on most clear cell and papillary RCC
🔹 ORR ~45% in heavily refractory, PD-1-pretreated #RCC, across 3 active dose levels
🔹 Benefit seen regardless of prior HIF inhibitor or TKI therapy
🔹 Requires step-up dosing. Main toxicities are early CRS (doses 1–2) and rash, because ENPP3 is also on skin mast cells. Both look manageable
🔹 Still open: durability and ENPP3 expression as a biomarker
Why has #kidneycancer lagged behind prostate cancer and SCLC on T-cell engagers, and how does it catch up? Possible next steps: combinations with PD-1, a move to frontline, and other targets like CD70.
Plus a detour to the 1998 World Cup final ⚽
⭐️MIBC session Friday 1pm CT: guoncologynow.com/videos/uro…
⭐️World Cup Final 🌐 3:30pm CT: guoncologynow.com/videos/uro…
@Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan
#OncoAlert #GUOnc #OncoX
📣 Registration Now Open for #IKCSNA26
Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America, where a multidisciplinary community of leading experts from academia, clinical care, industry and advocacy come together to share ideas, explore emerging trends and shape the future of kidney cancer research and care.
🗓️ November 19–21, 2026
📍 Dallas, Texas
🏨 Renaissance Dallas Hotel
Register 👉 kidneycancer.org/event/2026-…
@KidneyCancer @LauraBukavinaMD @QingZhangLab @bergsa83 @mkbupathi @ADESAIONCMD @AmyLuckenbaugh @virajmaster @spsutkaMD @ChadTangMD @MVossMD @TiansterZhang @PavlosMsaouel @salvolarosa @GEVaughan1
379
OncoAlert retweeted
Can ctDNA tell us who should get SBRT for oligoprogressive mCRPC?
jamanetwork.com/journals/jam…
Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy
A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial
In this prespecified analysis of the phase 2 TRAP trial, 77 patients with oligoprogressive metastatic castration-resistant #ProstateCancer received SBRT while continuing an androgen receptor pathway inhibitor.
➡️Pre-SBRT ctDNA positivity was associated with significantly shorter progression-free survival: median 3.0 vs 7.8 months for ctDNA-negative patients.
✅These findings suggest ctDNA status may help identify patients most likely to benefit from SBRT while continuing ARPI therapy.
@f_orlando_, @Dr_AJC, @nickva1, @y_suhughes, @FrancescaBZNY, @alison_tree, @AttardLab
OncoAlert retweeted
🚨 73.8% response rate in advanced TNBC: promising early data for pumitamig + nab-paclitaxel.
thelancet.com/journals/lanon…
Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
In this phase 1b/2 trial, first-line pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, plus nab-paclitaxel demonstrated encouraging activity in 42 patients with advanced or metastatic triple-negative #BreastCancer .
➡️ At 35.2 months’ median follow-up, the confirmed objective response rate was 73.8%, including one complete response.
➡️ Grade ≥3 toxicities included neutropenia, leukopenia, proteinuria, and febrile neutropenia. No treatment-related deaths occurred.
✅These findings support further evaluation in larger global trials.
OncoAlert retweeted
🧬 Can urine EV glycan signatures help us distinguish aggressive prostate cancer from indolent disease BEFORE committing patients to biopsy?
lnkd.in/exDkkJ4d
Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer
Could urine extracellular vesicle (EV) glycan profiling improve #ProstateCancer detection beyond PSA?
➡️ In this study of 135 men, Glycoflow analysis of post-DRE urine EVs improved discrimination of clinically significant prostate cancer (AUC 0.80 vs 0.71–0.72) and very significant disease (0.81–0.82 vs 0.72–0.73) when combined with clinical parameters.
✅ EV glycan profiling provided complementary diagnostic information, potentially improving biopsy decisions and reducing overdiagnosis, pending larger validation.
@sim1garz8
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
OncoAlert retweeted
What if instead of simply inhibiting the androgen receptor, we could rewire the complex that drives its activity?
nature.com/articles/s41586-0…
Domain-alteration chimeras rewire oncogenic complexes in prostate cancer
This study introduces DALTAC-1, a first-in-class domain-alteration chimera designed to rewire the androgen receptor (AR)–p300/CBP complex in metastatic castration-resistant #ProstateCancer .
➡️ By forcing a non-native interaction between AR and p300/CBP, DALTAC-1 locks the complex into a nonproductive state, profoundly suppressing AR-driven transcription.
✅The approach produced deep, durable tumor regressions across preclinical models while selectively targeting AR-dependent prostate cancer cells.
@ArulChinnaiyan, @Chinnaiyanlab, @Pixel_and_Path, @abhijitparolia, @EyunniSanjana, @yuanyuan_qiao, @rahulmannan, @UMich
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
OncoAlert retweeted
The eye can also be a target of immune activation. ICI ocular toxicity affects different ocular structures and may threaten vision. Early ophthalmologic recognition matters.
JIPO p.190 innovationsjournals-jipo.kgl…
@HajjarJoud @BettzyStephen @ANaingMD @AAO_ophth @OncoAlert
#JIPO #ION
🤖 Made with AI
OncoAlert retweeted
At 6 months, the two curves looked the same!
At 3 years: 53% vs 30% without progression.
Pembrolizumab alone vs chemo, dMMR endometrial cancer.
🧬In dMMR endometrial cancer, what does chemo still add?
@TheLancet @GOG @ESGO_society @OncoAlert @OpenMedicineHQ
Can patients with muscle-invasive bladder cancer avoid radical cystectomy?
From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸
Listen to the full discussion ⬇️
🎧 Apple: apple.co/4t9r8Ps
🎧 Spotify: bit.ly/4iPpf6Q

ALT The image shows three individuals seated on a stage during "The Uromigos Live & Unplugged" event in Nashville '26. The backdrop features bright lights and the event's logo. Text below the stage reads, "The Great Debate: Can We Spare the Bladder? Rethinking Bladder-Directed Therapy in MIBC." There is a silhouette of a city skyline and a guitar graphic at the bottom right.
On November 17, 2026, the FDA 🇺🇸granted accelerated approval to neladalkib for adults with ALK-positive locally advanced or metastatic #NSCLC #LungCancer 🫁previously treated with alectinib, or with ≥2 ALK TKIs plus platinum chemotherapy. In the single-arm ALKOVE-1 trial, ORR was 49% after alectinib alone (n=67) and 32% after multiple TKIs and chemotherapy (n=155). Among responders, about half had responses lasting ≥12 months in both cohorts, offering a new option.
Pinging Lung Cancer Faculty
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
OncoAlert retweeted
FDA grants accelerated approval to neladalkib (NVL-655) for advanced ALK positive NSCLC with prior TKI therapy. Based on ALKOVE-1 study - post alectinib RR 49%, more than half of responses ongoing at a year. Favorable tox profile. New best in class?
fda.gov/drugs/cancer-approva…
OncoAlert retweeted
FDA approves giredestrant + everolimus for adults with ER+/HER2− ESR1-mutated locally advanced or metastatic #BreastCancer :
🔹 Recurrence during or after adjuvant endocrine therapy, OR
🔹 Progression on ≥1 endocrine-based regimen in the metastatic setting
🧬 FoundationOne Liquid CDx is authorized as the companion diagnostic to detect ESR1 mutations
fda.gov/drugs/cancer-approva…
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
OncoAlert retweeted
🚀🚀 #YAP #TEAD también en @redaccionmedica @_SEOM @sanidadgob @OncoAlert
Https://teapawt.org/redaccionmedic…
🧬 La #Oncología recupera una vía molecular que llevaba años resistiéndose a los tratamientos.
La #investigación abre la puerta a una nueva generación de #terapias dirigidas contra el #cáncer. ¿Qué papel juega YAP/TEAD? 👇
buff.ly/TEXMnD3
OncoAlert retweeted
What should clinicians know about the updated @AmericanCancer prostate cancer screening guideline?
🎙️ Drs. Robert Smith and Andrew Wolf break down the major updates with our EIC Dr. Don Dizon in a new #CancerSpeak.
Listen: cancerspeak.podbean.com/e/pr…
@OncoAlert @ACSNews #PCSM
OncoAlert retweeted
My 2022 @JAMAOnc essay "Avoiding Checkmate", seems relevant for thinking into EGFR #lcsm
Post-osi EGFRm NSCLC:
➡️ Ami-chemo approved (MARIPOSA-2)
➡️ Dato-DXd (AA)
➡️ Ivonescimab ❌, OS missed
How do we plan line 3 at diagnosis?
doi.org/10.1001/jamaoncol.20…
@LungCancerRx @OncoAlert
OncoAlert retweeted
Hearing loss, tinnitus and vestibular dysfunction are easily overlooked among irAEs, yet can profoundly affect quality of life. Survival and survivorship go together.
JIPO p.188 innovationsjournals-jipo.kgl…
@HajjarJoud @BettzyStephen @ANaingMD @AAOHNS @OncoAlert
#JIPO #ION
🤖 Made with AI
📢 Happening Today | #SCLC Treatment in 2026–2027: What Is Changing?
📅 Today, 17 November 🕓 16:00–17:30 CET
👉 bit.ly/4ijiDMv
#LungCancer #Radiotherapy #Radonc
OncoAlert retweeted
An important question now is how best to position this combination in the treatment sequence. What will most influence its adoption in clinical practice?
@OncoAlert
29%PFS benefit
33%Treatment sequencing
19%ESR1 testing
19%Mature OS data
21 votes • 9 hours OncoAlert retweeted
New @Annals_Oncology study exploring ctDNA-guided pembro in resected dMMR tumours.
- 92% 2-year RFS in MRD- without treatment
- Despite ⬆️clearance in treated MRD+, 38% relapsed. Sustained clearance may be more informative
@OncoAlert @YJanjigianMD
annalsofoncology.org/article…
OncoAlert retweeted
🔬A randomized phase II trial found that adding toripalimab to modified FOLFIRINOX improved event-free survival in borderline resectable or locally advanced #PancreaticCancer.
➡️ Median EFS: 11.1 vs 9.6 months
🔸Tingbo Liang, MD, PhD | @JCO_ASCO
🔗 ascopost.com/news/november-2…





























